Oct 1 2010
Praesidian Capital, a leading provider of mezzanine capital for small and mid-sized companies, has invested $6 million in subordinated debt in Meta Pharmaceutical Services, a leading sales and marketing data services provider. The investment supports the recapitalization of Meta Pharmaceutical Services by DFW Capital Partners and management.
Meta Pharmaceutical Services is a leading provider of sales and marketing data and services to the pharmaceutical industry. The Company is engaged in three service lines: Data Reporting and Management, Direct Mail and Fulfillment, and Custom Programs. Meta's Data Reporting and Management as well as Direct Mail and Fulfillment service lines use sophisticated sales analytics and reporting tools to enhance applications and allow pharmaceutical companies to identify and communicate with physicians that are most likely to prescribe a given pharmaceutical product. The Company's Custom Programs service line assists pharmaceutical clients with administrative speaker, patient assistance, and voucher/rebate programs.
"Meta Pharmaceutical Services has sustained solid revenue and EBITDA growth amid the recession which can be attributed to its solid management team and long-term client relationships," said Neil Marks, Managing Partner at Praesidian Capital. "We are very excited to be a part of a company that is dedicated to its customer base and driven to explore new innovations for sustainable growth."
"We are delighted to have a long-term investor like Praesidian Capital as our partner," said Tom Lawrence, CEO of Meta Pharmaceutical Services. "With the financial support of Praesidian Capital and DFW Capital Partners, we are confident we will continue to attract new clients and additional engagements by developing and introducing new and innovative products and services."
"Meta Pharmaceutical Services has a reputation for leading sales and marketing data services to the pharmaceutical industry," said Keith Pennell, General Partner at DFW Capital Partners. "With the support of Praesidian Capital, the Company is in prime position for further development of products and services."